Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gentulizumab
- Development stage
- Discontinued
- Lead developer
- Changchun GeneScience Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Gentulizumab is a humanized IgG4 monoclonal antibody that targets CD47, an immune checkpoint protein often overexpressed on cancer cells. By binding to CD47, gentulizumab blocks the "don't eat me" signal that protects tumor cells from phagocytosis by macrophages and other immune cells. This mechanism promotes the destruction of malignant cells by the innate immune system. Gentulizumab has demonstrated potent antitumor activity in preclinical models and is being investigated for hematological malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), non-Hodgkin lymphoma (NHL), and advanced solid tumors. The drug is under development by Changchun GeneScience Pharmaceutical Co., Ltd., with clinical trials primarily conducted in China[2][3][4][6].
- Other names
- gentulizumabGENTULIZUMAB (anti-CD47 Humanized Monoclonal Antibody)
02
Targets
CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on gentulizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gentulizumab.